Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Feds Say Bayer Colon Supplement Makes Bogus Claims

By Pharmaceutical Processing | September 12, 2014

WASHINGTON (AP) — The federal government says Bayer is making unsupported claims in advertisements for its dietary supplement designed to help with digestion, in violation of a federal court order.

The Department of Justice filed a court motion Friday against the German conglomerate over its advertisements for Phillips’ Colon Health, which claims to prevent diarrhea, constipation, gas and bloating. Federal officials say the company does not have reliable scientific evidence to support those claims.

Bayer said in a statement it “is extremely disappointed and strongly disagrees” with the government action.

“Bayer believes that the product’s benefits for consumers are fully substantiated and supported. We will defend ourselves vigorously.”

Bayer is subject to a 2007 court order that prohibits the company from making unsubstantiated claims about its vitamins and dietary supplements. That order stemmed from an earlier federal complaint about the company’s marketing for its One-A-Day Weightsmart vitamins. Bayer paid $3.2 million to settle those allegations and pledged to stop making unsubstantiated claims for similar over-the-counter products.

The government’s motion highlights the company’s multimillion dollar print and television campaign featuring “the Colon Lady,” a spokeswoman who asks people about their colon health. U.S. consumers have spent hundreds of millions of dollars on the company’s product, according to the government release.

“The Department of Justice will not tolerate companies that seek to gain an unfair advantage over their competitors by promoting to consumers unsubstantiated claims about the health benefits of their products,” said Stuart Delery, an assistant attorney general.

The government motion was filed in the federal district court of New Jersey with assistance from the Federal Trade Commission.

Bayer’s U.S. headquarters is in Whippany, N.J.

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards